Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Anti-Drug Antibodies May Affect RA Treatment

Lara C. Pullen, PhD  |  June 5, 2017

A recent study examined the level of anti-drug antibodies (ADAs) in RA patients taking the TNF inhibitors adalimumab, infliximab and etanercept. Study patients without ADAs experienced better clinical outcomes, while patients with detectable ADAs had significantly lower serum trough drug concentrations…

U.S. State, Local Government Lawsuits Over Opioids Face Uphill Battle

Nate Raymond  |  June 5, 2017

BOSTON (Reuters)—A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success. Ohio on Wednesday became the latest, and largest, state or local government to bring…

Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017

Reuters Staff  |  June 5, 2017

(Reuters)—Pfizer Inc. has hiked the price of nearly a hundred drugs by an average of 20 percent so far this year in the U.S., the Financial Times reported on Friday. The U.S. drug maker raised the list price of 91 medicines—including that of its erectile dysfunction treatment, Viagra, and its pain drug, Lyrica—on June 1…

Older Adults May Stave Off Arthritis Knee Pain with Fiber

Anne Harding  |  June 4, 2017

(Reuters Health)—Older people who eat the most fiber are at lower risk of developing knee pain and stiffness due to osteoarthritis (OA), new research shows.1 Diets rich in fiber from plant-based foods have clear health benefits, such as lower cholesterol, better-controlled blood sugar and a healthier weight, but most people in the U.S. don’t eat…

Voclosporin Promising for Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  June 4, 2017

In a recent clinical trial, voclosporin proved safe and effective at both low and high doses as a treatment for lupus nephritis…

Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease

Arthritis Care & Research  |  June 4, 2017

New research has examined the risk of cardiovascular disease (CVD), as well as myocardial infarction and ischemic stroke, for patients with systemic lupus erythematosus (SLE) in a large-scale population-based study. Researchers found that patients with SLE have a greater than two-fold increased risk of developing CVD. This risk is greatest during the first year after diagnosis and remains elevated for at least five years…

Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails

Reuters Staff  |  June 1, 2017

NEW YORK (Reuters Health)—The selective interleukin-17A inhibitor ixekizumab improved signs and symptoms of active psoriatic arthritis (PsA) in patients who had failed prior biologic therapy in the phase 3 SPIRIT-P2 trial. The SPIRIT-P2 trial joins the earlier phase 3 SPIRIT-P1 trial, which showed that ixekizumab was safe and effective in PsA patients not previously treated…

Ohio Sues Five Drug Companies Over Opioid Crisis

Chris Kenning  |  May 31, 2017

CHICAGO (Reuters)—Ohio Attorney General Mike DeWine said on Wednesday his office sued five major drug manufacturers, accusing them of misrepresenting the risks of prescription opioid painkillers and so helping fuel a sky-rocketing drug addiction epidemic. A growing number of state and local governments are suing drugmakers and distributors, seeking to hold them accountable for the…

BAFF: A Fulcrum Between Resistance to Infection & Autoimmunity

Lara C. Pullen, PhD  |  May 31, 2017

New research has linked a TNFSF13B variant and B cell activating factor (BAFF), a common therapeutic target, with multiple sclerosis and systemic lupus erythematosus. The variant is a disease-risk allele associated with increased levels of soluble BAFF…

Building on Basics: Why I Am an Advocate for Rheumatology

Chris Morris, MD  |  May 31, 2017

If you speak to any advocate for rheumatology, each of us will tell you we’ve had an “a-ha” moment where we learned the importance of advocacy; my own came a dozen years ago. I was meeting with a legislative aide to a local Congressional representative who was a senior member of the committee overseeing Medicare….

  • « Previous Page
  • 1
  • …
  • 201
  • 202
  • 203
  • 204
  • 205
  • …
  • 317
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences